PMN on Nasdaq

ProMIS Neurosciences Inc.

Pharmaceutical preparations company based in Toronto, listed on Nasdaq (PMN). Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

TickerPMN on Nasdaq¹
IndustryPharmaceutical Preparations¹
HeadquartersToronto, Canada¹
Incorporated inCanada (Federal Level)²
Business addressSuite 200, 1920 Yonge Street, Toronto, A6 M4S 3E2²
Filer category, Emerging growth company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

ProMIS has in-licensed a patented technology platform with the potential to deliver a portfolio of antibody therapies, therapeutic vaccines, and other therapies derived from antibodies for neurodegenerative diseases and other misfolded protein diseases, which may include Alzheimer’s disease, multiple system atrophy, amyotrophic lateral sclerosis, frontotemporal lobar degeneration, Parkinson’s disease, progressive supranuclear palsy, corticobasal degeneration (respectively, AD, MSA, ALS, FTLD, PD, PSP, CBD) and schizophrenia. A common biologic cause contributes to each of these conditions, in that certain proteins, which normally perform a needed function, when misfolded, can cause neuronal degeneration and death, contributing to morbidity and mortality. ProMIS’ technology platform is an example of the advances in drug discovery enabled by computational power, in silico discovery, and/or …³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income⁴⁵⁶⁷-$40.2M in 2025+384% since 2021

Net income⁴⁵⁶⁷-$39.7M in 2025+306% since 2021

Every line of the income statement as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Research and development	$33.4M	$10.6M
General and administrative	$6.8M	$6.2M
Total operating expenses	$40.2M	$16.8M
Loss from operations	-$40.2M	-$16.8M
Change in fair value of financial instruments	$5.6K	$22.6M
Interest expense		-$76.8K
Other income	$442.6K	$626.2K
Loss on issuance of Common Shares, warrants, and pre-funded warrants in July 2024 PIPE		-$3.5M
Total other income, net	$448.2K	$19.6M
Net (loss) income	-$39.7M	$2.8M
Net (loss) income per share, basic	-$22.61	$2.68
Net (loss) income per share, diluted	-$22.61	$2.63
Weighted-average outstanding Common Shares, basic	1.8M shares	1.0M shares
Weighted-average outstanding Common Shares, diluted	1.8M shares	1.1M shares

Total assets⁴⁵⁶⁷$9.2M in 2025−48% since 2021

Total liabilities⁴⁵⁶⁷$10.4M in 2025−14% since 2021

Shareholders’ equity⁴⁵⁶⁷-$1.3M in 2025+58% since 2020

Cash⁴⁵⁶⁷$6.1M in 2025+658% since 2020

Long-term debt⁴⁵$0 in 2023

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.⁷

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$6.1M	$13.3M
Short-term investments	$33.8K	$33.1K
Prepaid expenses and other current assets	$3.0M	$5.6M
Total current assets	$9.2M	$18.9M
Total assets	$9.2M	$18.9M
Accounts payable	$2.5M	$1.7M
Accrued liabilities	$7.9M	$481.0K
Total current liabilities	$10.4M	$2.2M
Share-based compensation liability	$29.2K	$199.3K
Warrant liability		$5.6K
Total liabilities	$10.4M	$2.4M
Additional paid-in capital	$129.5M	$107.5M
Accumulated other comprehensive loss	-$371.2K	-$371.2K
Accumulated deficit	-$130.4M	-$90.7M
Total shareholders' (deficit) equity	-$1.3M	$16.5M	$3.8M
Total liabilities and shareholders' (deficit) equity	$9.2M	$18.9M
Common shares, par value	$0	$0
Common shares, shares issued	2.2M shares	1.3M shares
Common shares, shares outstanding	2.2M shares	1.3M shares

Period ending	2025-12-31	2024-12-31	2023-12-31
Cash	$6.1M	$13.3M
Short-term investments	$33.8K	$33.1K
Prepaid expenses and other current assets	$3.0M	$5.6M
Total current assets	$9.2M	$18.9M
Total assets	$9.2M	$18.9M
Accounts payable	$2.5M	$1.7M
Accrued liabilities	$7.9M	$481.0K
Total current liabilities	$10.4M	$2.2M
Share-based compensation liability	$29.2K	$199.3K
Warrant liability		$5.6K
Total liabilities	$10.4M	$2.4M
Additional paid-in capital	$129.5M	$107.5M
Accumulated other comprehensive loss	-$371.2K	-$371.2K
Accumulated deficit	-$130.4M	-$90.7M
Total shareholders' (deficit) equity	-$1.3M	$16.5M	$3.8M
Total liabilities and shareholders' (deficit) equity	$9.2M	$18.9M
Common shares, par value	$0	$0
Common shares, shares issued	2.2M shares	1.3M shares
Common shares, shares outstanding	2.2M shares	1.3M shares

Cash from operations⁴⁵⁶⁷-$28.1M in 2025+202% since 2021

Capital spending⁴⁵$2.0K in 2022−67% since 2021

Free cash flow⁴⁵-$17.0M in 2022+83% since 2021

Every line of the cash flow as filed: the last 2 fiscal years, latest first.⁷

Period ending	2025-12-31	2024-12-31
Net (loss) income	-$39.7M	$2.8M
Share-based compensation expense	$857.6K	$825.8K
Loss on issuance of common shares, warrants, and pre-funded warrants in July 26, 2024 PIPE		$3.5M
Change in fair value of financial instruments	-$5.6K	-$22.6M
Prepaid expenses and other current assets	$2.6M	-$4.6M
Accounts payable	$806.0K	-$6.1M
Accrued liabilities	$7.4M	-$1.0M
Net cash used in operating activities	-$28.1M	-$27.2M
Purchase of short-term investments	-$33.8K	-$33.1K
Maturity of short-term investment	$33.1K	$32.4K
Net cash used in investing activities	-$702	-$693
Proceeds from issuance of Common Shares pursuant to 2025 and 2024 ATM offering, respectively, net of issuance costs	$708.5K	$190.3K
Proceeds from exercise of pre-funded warrants	$3.0K	$28.0K
Net cash provided by financing activities	$20.9M	$27.9M
Net (decrease) increase in cash	-$7.2M	$693.0K
Reclassification of July 2024 PIPE warrants from liability to equity		$8.7M
Decrease in share-based compensation liability on CAD denominated share options increasing additional paid-in-capital	-$170.1K	$222.7K
Cash paid for interest		$76.8K

Compare ProMIS Neurosciences Inc. with another company

Leadership

Who has led ProMIS Neurosciences Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

2025

Chief executive officerNeil K. Warma Jan 5, 2024 to now¹⁰
Chief executive officerEugene Williams Jul 7, 2022 to Jul 12, 2022¹¹
Chief executive officerGail M. Farfel Sep 20, 2022 to Aug 25, 2023¹²
ChairEugene Williams Jul 7, 2022 to Jul 12, 2022¹¹
Chief financial officerDaniel E. Geffken Jul 7, 2022 to Oct 30, 2023¹³
Chief operating officerGavin T. Malenfant Jul 7, 2022 to Oct 30, 2023¹⁴

Board members and other officers (15)

Chief Development OfficerJohanne Kaplan Mar 16, 2023 to now¹⁵
Chief Medical OfficerLarry Douglas Altstiel Jul 7, 2022 to now¹⁶
Principal Accounting OfficerMax A. Milbury Jul 7, 2022 to now¹⁷
Chief Scientific OfficerNeil Cashman Jul 7, 2022 to now¹⁸
Board memberSlanix Paul Alex Oct 24, 2025 to now¹⁹
Board memberGail M. Farfel Aug 25, 2023 to Aug 25, 2023²⁰
Board memberGavin T. Malenfant Oct 30, 2023 to Oct 30, 2023²¹
Board memberJosh Mandel-Brehm Jul 7, 2022 to now²²
Board memberMadge K. Shafmaster Jul 7, 2022 to now²³
Board memberNeil Cashman Jul 7, 2022 to now¹⁸
Board memberNeil K. Warma Jul 7, 2022 to now²⁴
Board memberPatrick D. Kirwin Jul 7, 2022 to now²⁵
Board memberRichard J. Gregory Jul 7, 2022 to Jul 7, 2022²⁶
Board memberWilliam W. Wyman Jul 7, 2022 to now²⁷
Board memberEugene Williams Dec 6, 2022 to now²⁸

Named in SEC Form D filings

People the company listed in its private-offering notices.

DirectorMaggie T. Shafmaster named Oct 21, 2022²⁹

Former names

AMORFIX LIFE SCIENCES LTDAug 29, 2006 to Nov 3, 2014²

Timeline

Jan 5, 2024New chief executive Neil K. Warma becomes CEO¹⁰
Sep 20, 2022New chief executive Gail M. Farfel becomes CEO¹²
Jul 7, 2022New chief executive Eugene Williams becomes CEO¹¹

Filings

319 filings to the SEC since October 2021: 5 annual reports, 13 quarterly reports, 61 major events, 105 insider forms, 41 large holders, 1 private raises, 93 other. The latest 20:

The 319 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

31 open-market trades by officers, directors and large owners since October 2021: 30 buys and 1 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Aug 5, 2026	Kaplan JohanneChief Development Officer	Buy	2,280	$13.30	$30.3K	Form 4
Apr 22, 2026	Kirwin Patrick D.Director	Buy	4,000	$11.33	$45.3K	Form 4
Mar 5, 2026	Williams EugeneDirector	Buy	2,000	$24.40	$48.8K	Form 4
Mar 4, 2026	Williams EugeneDirector	Buy	2,000	$24.00	$48.0K	Form 4
Mar 3, 2026	Williams EugeneDirector	Buy	1,000	$21.89	$21.9K	Form 4
Mar 2, 2026	Williams EugeneDirector	Buy	1,000	$22.53	$22.5K	Form 4
Feb 19, 2026	Kaplan JohanneChief Development Officer	Buy	1,629	$15.35	$25.0K	Form 4
Feb 3, 2026	Yu Fan10% owner	Buy	700,741	$12.13	$8.5M	Form 4
Oct 3, 2025	Milbury Max A.Principal Accounting Officer	Buy	30,392	$0.49	$14.9K	Form 4
Jun 30, 2025	GORDON MICHAEL S	Sale	93,223			Form 4
Feb 10, 2025	Cashman NeilChief Scientific Officer	Buy	15,000	$0.97	$14.6K	Form 4
Sep 24, 2024	Shafmaster Madge K.Director	Buy	70,000	$1.30	$91.0K	Form 4
Sep 23, 2024	Shafmaster Madge K.Director	Buy	70,000	$1.28	$89.6K	Form 4
Sep 20, 2024	Shafmaster Madge K.Director	Buy	60,000	$1.25	$75.0K	Form 4
Sep 17, 2024	GORDON MICHAEL S	Buy	16,292	$1.40	$22.8K	Form 4
Sep 16, 2024	GORDON MICHAEL S	Buy	76,931	$1.22	$93.9K	Form 4
Aug 14, 2024	Kirwin Patrick D.Director	Buy	10,000	$1.25	$12.5K	Form 4
Jul 31, 2024	Title 19 Promis	Buy	465,116			Form 4
Jul 31, 2024	GORDON MICHAEL S	Buy	465,116			Form 4
Jul 31, 2024	Sclar Jeremy M.10% owner	Buy	697,674			Form 4

All 31 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

GREAT POINT PARTNERS LLCSCHEDULE 13G/A, 8 filings Aug 5, 2024 to Aug 14, 2026³⁰
Wellington Biomedical Innovation Master Investors (Cayman) II L.P.SCHEDULE 13G/A, 2 filings Mar 18, 2026 to Aug 13, 2026³¹
Wellington Management CompanySCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 13, 2026³²
Michael S. GordonSCHEDULE 13G/A, 6 filings Oct 21, 2022 to May 7, 2026³³
Janus Henderson Group Ltd.SCHEDULE 13G, 1 filing Apr 7, 2026³⁴
ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 5 filings Nov 14, 2024 to Feb 17, 2026³⁵
Trails Edge Capital Partners, LPSCHEDULE 13G, 1 filing Feb 10, 2026³⁶
Deep Track Capital, LPSCHEDULE 13G, 1 filing Feb 6, 2026³⁷
ABG Management Ltd.SCHEDULE 13D/A, 4 filings Aug 4, 2025 to Feb 5, 2026³⁸
SPHERA FUNDS MANAGEMENT LTD.SCHEDULE 13G/A, 4 filings Aug 30, 2023 to Feb 5, 2026³⁹
Jeremy M. SclarSCHEDULE 13G/A, 5 filings Feb 3, 2023 to Oct 15, 2025⁴⁰
Shaf QIC LLCSCHEDULE 13G/A, 2 filings Oct 16, 2024 to Jul 31, 2025⁴¹

Money raised

Private offerings the company reported to the SEC on Form D.

Oct 11, 2022Raised $7.5 million in a private offering of equity Form D: $10.1 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 27. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
Jupiter Topco LLC	1,292,757	$17.0M	0.0%	New
Deep Track Capital, LP	835,655	$11.0M	0.2%	No change
Wellington Management Group Llp	696,378	$9.2M	0.0%	No change
Ally Bridge Group (NY) LLC	620,319	$8.2M	10.5%	+206,100
Trails Edge Capital Partners, LP	557,103	$7.3M	1.2%	No change
Woodline Partners LP	441,911	$5.8M	0.0%	+46,616
Yu Fan	329,760	$4.3M	4.0%	No change
Sphera Funds Management Ltd.	325,591	$4.3M	0.6%	No change
Squadron Capital Management LLC	324,977	$4.3M	1.5%	No change
Ikarian Capital, LLC	205,000	$2.7M	0.4%	+150,000
Ameriprise Financial Inc	185,700	$2.4M	0.0%	New
Adage Capital Partners Gp, L.l.c.	164,275	$2.2M	0.0%	+25,000
683 Capital Management, LLC	95,000	$1.3M	0.1%	+2,150
ADAR1 Capital Management, LLC	92,850	$1.2M	0.1%	−2,500
Great Point Partners LLC	86,150	$1.1M	0.3%	−285,252
Boothbay Fund Management, LLC	62,078	$816.9K	0.0%	+46,035
Millennium Management LLC	56,045	$737.6K	0.0%	−21,876
Bank Of Montreal /can/	11,371	$149.6K	0.0%	New
Seven Fleet Capital Management LP	10,600	$139.5K	0.0%	No change
Morgan Stanley	7,559	$99.5K	0.0%	New
UBS Group AG	691	$9.1K	0.0%	−609
Osaic Holdings, Inc.	360	$4.7K	0.0%	No change
Royal Bank Of Canada	218	$3.0K	0.0%	−50
Steward Partners Investment Advisory, LLC	94	$1.2K	0.0%	−6
Federation des caisses Desjardins du Quebec	10	$131	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARProMIS Neurosciences Inc. filings on SEC EDGAR
2
SEC EDGARProMIS Neurosciences Inc. filings on SEC EDGAR
3
SEC EDGARProMIS Neurosciences Inc. annual report, Item 1 (Business)
4
SEC EDGARProMIS Neurosciences Inc. 10-K for fiscal 2021
5
SEC EDGARProMIS Neurosciences Inc. 10-K for fiscal 2022
6
SEC EDGARProMIS Neurosciences Inc. 10-K for fiscal 2023
7
SEC EDGARProMIS Neurosciences Inc. 10-K for fiscal 2024
8
SEC EDGARProMIS Neurosciences Inc. 10-Q for fiscal 2026
9
SEC EDGARProMIS Neurosciences Inc. 10-Q for fiscal 2026
10
SEC EDGARNeil K. Warma, Chief executive officer
11
SEC EDGAREugene Williams, Chief executive officer
12
SEC EDGARGail M. Farfel, Chief executive officer
13
SEC EDGARDaniel E. Geffken, Chief financial officer
14
SEC EDGARGavin T. Malenfant, Chief operating officer
15
SEC EDGARJohanne Kaplan, Chief Development Officer
16
SEC EDGARLarry Douglas Altstiel, Chief Medical Officer
17
SEC EDGARMax A. Milbury, Principal Accounting Officer
18
SEC EDGARNeil Cashman, Chief Scientific Officer
19
SEC EDGARSlanix Paul Alex, Board member
20
SEC EDGARGail M. Farfel, Board member
21
SEC EDGARGavin T. Malenfant, Board member
22
SEC EDGARJosh Mandel-Brehm, Board member
23
SEC EDGARMadge K. Shafmaster, Board member
24
SEC EDGARNeil K. Warma, Board member
25
SEC EDGARPatrick D. Kirwin, Board member
26
SEC EDGARRichard J. Gregory, Board member
27
SEC EDGARWilliam W. Wyman, Board member
28
SEC EDGAREugene Williams, Board member
29
SEC EDGARProMIS Neurosciences Inc. Form D naming Maggie T. Shafmaster
30
SEC EDGARGREAT POINT PARTNERS LLC SCHEDULE 13G/A on ProMIS Neurosciences Inc.
31
SEC EDGARWellington Biomedical Innovation Master Investors (Cayman) II L.P. SCHEDULE 13G/A on ProMIS Neurosciences Inc.
32
SEC EDGARWellington Management Company SCHEDULE 13G/A on ProMIS Neurosciences Inc.
33
SEC EDGARMichael S. Gordon SCHEDULE 13G/A on ProMIS Neurosciences Inc.
34
SEC EDGARJanus Henderson Group Ltd. SCHEDULE 13G on ProMIS Neurosciences Inc.
35
SEC EDGARARMISTICE CAPITAL, LLC SCHEDULE 13G/A on ProMIS Neurosciences Inc.
36
SEC EDGARTrails Edge Capital Partners, LP SCHEDULE 13G on ProMIS Neurosciences Inc.
37
SEC EDGARDeep Track Capital, LP SCHEDULE 13G on ProMIS Neurosciences Inc.
38
SEC EDGARABG Management Ltd. SCHEDULE 13D/A on ProMIS Neurosciences Inc.
39
SEC EDGARSPHERA FUNDS MANAGEMENT LTD. SCHEDULE 13G/A on ProMIS Neurosciences Inc.
40
SEC EDGARJeremy M. Sclar SCHEDULE 13G/A on ProMIS Neurosciences Inc.
41
SEC EDGARShaf QIC LLC SCHEDULE 13G/A on ProMIS Neurosciences Inc.